/

INAB

IN8bio, Inc.Closed

1.18−0.05 −4.07%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.18 0.00%

Open

1.25

Prev close

1.23

Day range

1.181.26

52-week range

0.88002.73

Volume

62.67K1.10×

Mkt cap

11.63M

P/E ttm

—

Fwd P/E

-1.24

EPS ttm

-1.62

Div yield

0.00%

Earnings

—

From 52w high

−56.78%

Price Chart

Yahoo Finance · delayed

INABOct 13, 2026O 1.25H 1.26L 1.18C 1.18−0.05 (−4.07%)Vol 62.70K

SMA 501.16
SMA 2001.54

1Y change −43.81% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INAB IN8bio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −15.11%
1 month: +10.28%
3 months: −14.49%
6 months: −14.49%
Year to date: −49.57%
1 year: −45.62%

Valuation & ownership

Market cap: 11.63M
Enterprise value: −4.15M
P/E (ttm): —
Forward P/E: -1.24
PEG ratio: —
Price / book: 0.63
Price / sales (ttm): —
EV / EBITDA: 0.23
EPS (ttm): -1.62
EPS (forward): -0.9500
Beta (5y monthly): 0.30
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 9.86M
Float: 7.18M
Short % of float: 0.53%
Short ratio (days): 1.12
Held by insiders: 7.58%
Held by institutions: 38.45%
Avg volume (3m): 56.74K
50-day average: 1.15
200-day average: 1.54
52-week change: −45.62%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 44.4
vs 50-day SMA: +2.06%
vs 200-day SMA: −23.20%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.13%
Realised vol (20d, ann.): 67.7%
From 52-week high: −56.78%
From 52-week low: +34.09%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

7.00

+493.22% implied

Low 5.00Median 6.00High 10.00

Recommendation trend

Now3 / 0 / 0
1m ago4 / 0 / 0

Buy / hold / sell counts

DES

About IN8bio, Inc.

Yahoo Finance profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 18
Headquarters: New York, NY, United States
Website: in8bio.com
Officers: Mr. Tai-Wei Ho Co-Founder, CEO & Director

SEAS

Seasonality · INAB

2021–2026 · monthly returns

Strongest month May +26.14%Weakest month Jun −32.21%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-15.8	-13.7	-12.9	-0.7	27.2	-24.6	-26.6	6.3	20.9	-11.3			−49.6%
2025	-0.4	5.1	-38.3	1.8	-12.4	-52.9	1.9	3.8	-1.8	-10.1	1.5	18.2	−69.6%
2024	-5.8	-14.6	6.3	-13.6	16.7	-28.8	-0.8	-37.4	-48.7	3.7	8.9	-15.7	−81.4%
2023	-0.6	-33.4	-15.0	12.3	108.2	-49.3	-23.4	-11.0	-1.0	-5.8	-15.3	66.3	−40.3%
2022	-23.2	24.6	-20.7	-27.9	-7.9	2.3	12.4	2.0	-22.0	-3.5	-10.8	32.8	−47.4%
2021								-32.0	0.7	10.8	-22.8	-25.1	−56.1%

INSD

Insider Activity · INAB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 26, 2026	Fairbairn Emily WangDirector	Stock Gift at price 0.00 per share.	724.6K	—
Dec 21, 2025	Fairbairn Emily WangDirector	Stock Award(Grant) at price 1.38 per share.	724.6K	$1000.00K
Dec 21, 2025	Brandt Peter CDirector	Stock Award(Grant) at price 1.38 per share.	72.5K	$100.00K
Dec 21, 2025	Roemer Alan S.Director	Stock Award(Grant) at price 1.38 per share.	36.2K	$50.00K
Dec 21, 2025	Ho William Tai WeiChief Executive Officer	Stock Award(Grant) at price 1.38 per share.	36.2K	$50.00K
Dec 21, 2025	Mccall Patrick CpaChief Financial Officer	Stock Award(Grant) at price 1.38 per share.	7.2K	$10.00K
Dec 21, 2025	Rochlin Kate Ph.D.Chief Operating Officer	Stock Award(Grant) at price 1.38 per share.	7.2K	$10.00K
Apr 29, 2025	Brandt Peter CDirector	Conversion of Exercise of derivative security at price 0.18 per share.	163.9K	$30.23K
Apr 29, 2025	Roemer Alan S.Director	Conversion of Exercise of derivative security at price 0.18 per share.	113.5K	$20.92K
Apr 29, 2025	Mccall Patrick CpaChief Financial Officer	Conversion of Exercise of derivative security at price 0.18 per share.	15K	$2.77K
Apr 29, 2025	Rochlin Kate Ph.D.Chief Operating Officer	Conversion of Exercise of derivative security at price 0.18 per share.	12.3K	$2.27K

13F

Investors Holding INAB

latest 13F filings of 29 followed managers

Investors holding INAB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$17.1K	0.00%	12.10K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

INAB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INAB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About IN8bio, Inc.

Seasonality · INAB

Insider Activity · INAB

Congress Trades · INAB

Investors Holding INAB

Investors Holding INAB

Congress Trades · INAB

Insider Activity · INAB

Seasonality · INAB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About IN8bio, Inc.

Financial Snapshot

Earnings & Dividends

News